[Federal Register: September 16, 2004 (Volume 69, Number 179)]
[Notices]
[Page 55824]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr16se04-64]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee on Special Studies Relating to the Possible
Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch
Hand Advisory Committee); Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Advisory Committee on Special Studies Relating
to the Possible Long-Term Health Effects of Phenoxy Herbicides and
Contaminants (Ranch Hand Advisory Committee).
General Function of the Committee: To advise the Secretary and the
Assistant Secretary for Health concerning its oversight of the conduct
of the Ranch Hand study by the U.S. Air Force and provide scientific
oversight of the Department of Veterans Affairs (VA) Army Chemical
Corps Vietnam Veterans Health Study, and other studies in which the
Secretary or the Assistant Secretary for Health believes involvement by
the committee is desirable.
Date and Time: The meeting will be held on September 22, 2004, 8
a.m. to 4:30 p.m.
Location: Food and Drug Administration, 5630 Fishers Lane, rm.
1066, Rockville, MD 20857.
Contact Person: Leonard Schechtman, National Center for
Toxicological Research, Food and Drug Administration, 5600 Fishers
Lane, rm. 16-85, Rockville, MD 20857, 301-827-6696, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512560. Please call the Information Line
for up-to-date information on this meeting.
Agenda: The Air Force will present for review to The Ranch Hand
Advisory Committee the following chapters from the ongoing study:
Chapter 19, ``Immunology;'' chapter 8, ``Covariates;'' chapter 12,
``Psychology;'' chapter 16, ``Hematology;'' chapter 15,
``Cardiovascular;'' chapter 7, ``Statistical Methods;'' chapter 5,
``Study Selection and Participation;'' and chapter 18, ``Endocrine.''
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by September 20,
2004. Oral presentations from the public will be scheduled on September
22, 2004, between approximately 12:15 p.m. and 12:40 p.m. Time allotted
for each presentation may be limited.
Those desiring to make formal oral presentations should notify the
contact person before September 20, 2004, and submit a brief statement
of the general nature of the evidence or arguments they wish to
present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their
presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Leonard Schechtman
at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 13, 2004.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 04-21009 Filed 9-14-04; 2:52 pm]
BILLING CODE 4160-01-S